Arvinas to Participate in Upcoming Virtual Investor Conferences
10 mars 2021 16h30 HE
|
Arvinas Inc.
NEW HAVEN, Conn., March 10, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
01 mars 2021 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., March 01, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation,...
Arvinas, Inc. Announces Exercise of Underwriters’ Option to Purchase Additional Shares
28 déc. 2020 16h30 HE
|
Arvinas Inc.
NEW HAVEN, Conn., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its...
Arvinas, Inc. Announces Pricing of $400 Million Public Offering of Common Stock
15 déc. 2020 20h35 HE
|
Arvinas Inc.
NEW HAVEN, Conn., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its...
Arvinas, Inc. Announces Proposed Offering of Common Stock
14 déc. 2020 16h06 HE
|
Arvinas Inc.
NEW HAVEN, Conn., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its...
Arvinas Releases Interim Clinical Data Further Demonstrating the Powerful Potential of PROTAC® Protein Degraders ARV-471 and ARV-110
14 déc. 2020 07h00 HE
|
Arvinas Inc.
– ARV-471 demonstrates evidence of anti-tumor activity, and potential for best-in-class safety, and estrogen receptor (ER) degradation profile and robust efficacy signals in a heavily pretreated...
Arvinas to Participate in Upcoming Virtual Investor Conferences
25 nov. 2020 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas to Present at the Citi 15th Annual BioPharma Virtual Conference
04 sept. 2020 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas Reports Second Quarter 2020 Financial Results and Provides Corporate Update
04 août 2020 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation,...
Arvinas To Present at the Wedbush PacGrow Healthcare Conference
07 août 2019 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn. , Aug. 07, 2019 (GLOBE NEWSWIRE) -- Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that...